NAACCR Item #3931: Serum Beta-2 Microglobulin Pretreatment Level
| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 3,931 | 1 | NAACCR | 2018 | 18 |
NAACCR XML: Tumor.serumBeta2MicroglobulinPretxLvl
Description
Serum Beta-2 Microglobulin is a protein that is found on the surface of many cells and plentiful on the surface of white blood cells. Increased production or destruction of these cells causes Serum β2 (beta-2) Microglobulin level to increase. Elevated Serum β2 (beta-2) Microglobulin level is a prognostic factor for plasma cell myeloma.
Rationale
Serum Beta-2 Microglobulin Pretreatment Level is a prognostic factor required in AJCC 8th edition, Chapter 82 Plasma Cell Myeloma and Plasma Cell Disorders, for staging of plasma cell myeloma.
Codes
| 0 | β2-microglobulin \<3.5 mg/L |
| 1 | β2-microglobulin =3.5 mg/L \<5.5 mg/L |
| 2 | β2-microglobulin =5.5 mg/L |
| 5 | Schema Discriminator 1: Plasma Cell Myeloma Terminology coded to 1 or 9 |
| 7 | Test ordered, results not in chart |
| 9 | Not documented in medical record Serum Beta-2 Microglobulin Pretreatment Level not assessed or unknown if assessed |
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.